Credit: Komsan Loonprom/Shutterstock. Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating ...
The agreement grants the Japanese pharma the worldwide license to initially use Sangamo's proprietary neurotropic adeno-associated virus (AAV) capsid, dubbed STAC-BBB, for one target. The idea is ...
Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating neurological diseases. Astellas will ...